James A. McCarthy
Corporate Officer/Principal at Association of Corporate Growth
Profile
James A.
McCarthy is currently a member of the Association of Corporate Growth and the Licensing Executives Society.
Previously, he worked as a Principal at Bristol Myers Squibb Co. and Eli Lilly & Co. He also served as the Vice President-Corporate Development at Technology Innovations LLC and PharmaVentures Ltd.
From 2008 to 2011, he was the Senior Vice President-Corporate Development at Egen, Inc.
James A. McCarthy active positions
Companies | Position | Start |
---|---|---|
Association of Corporate Growth | Corporate Officer/Principal | - |
Licensing Executives Society | Corporate Officer/Principal | 05/08/2009 |
Former positions of James A. McCarthy
Companies | Position | End |
---|---|---|
Egen, Inc.
Egen, Inc. Medical SpecialtiesHealth Technology Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL. | Corporate Officer/Principal | 01/05/2011 |
PharmaVentures Ltd.
PharmaVentures Ltd. Investment ManagersFinance Pharma Ventures Ltd. provides advisory services on life sciences transactions. It offers mergers and acquisitions, licensing, strategy and valuation, and expert services. The firm's industry coverage includes pharmaceuticals, biologics, drug delivery systems, diagnostics, medical devices, including telemedicine, medical software. The company is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Technology Innovations LLC | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
Private companies | 5 |
---|---|
Egen, Inc.
Egen, Inc. Medical SpecialtiesHealth Technology Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL. | Health Technology |
Association of Corporate Growth | |
Technology Innovations LLC | |
Licensing Executives Society | |
PharmaVentures Ltd.
PharmaVentures Ltd. Investment ManagersFinance Pharma Ventures Ltd. provides advisory services on life sciences transactions. It offers mergers and acquisitions, licensing, strategy and valuation, and expert services. The firm's industry coverage includes pharmaceuticals, biologics, drug delivery systems, diagnostics, medical devices, including telemedicine, medical software. The company is headquartered in Oxford, the United Kingdom. | Finance |
- Stock Market
- Insiders
- James A. McCarthy